Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALACTIC-1 in idiopathic pulmonary fibrosis
2018-002664-73Phase 2Completed
- Sponsor
- Galecto, Inc.
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing GB0139 with Placebo (2 arms). Primary endpoint: Annual rate of decline in forced vital capacity. Started Dec 2018; status: completed.
02
Drugs
GB0139
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2018-002664-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002664-73.